Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

Blood
Renato BassanAlessandro Rambaldi

Abstract

Clinical risk classification is inaccurate in predicting relapse in adult patients with acute lymphoblastic leukemia, sometimes resulting in patients receiving inappropriate chemotherapy or stem cell transplantation (SCT). We studied minimal residual disease (MRD) as a predictive factor for recurrence and as a decisional tool for postconsolidation maintenance (in MRD(neg)) or SCT (in MRD(pos)). MRD was tested at weeks 10, 16, and 22 using real-time quantitative polymerase chain reaction with 1 or more sensitive probes. Only patients with t(9;22) or t(4;11) were immediately eligible for allogeneic SCT. Of 280 registered patients (236 in remission), 34 underwent an early SCT, 60 suffered from relapse or severe toxicity, and 142 were evaluable for MRD at the end of consolidation. Of these, 58 were MRD(neg), 54 MRD(pos), and 30 were not assessable. Five-year overall survival/disease-free survival rates were 0.75/0.72 in the MRD(neg) group compared with 0.33/0.14 in MRD(pos) (P = .001), regardless of the clinical risk class. MRD was the most significant risk factor for relapse (hazard ratio, 5.22). MRD results at weeks 16 to 22 correlated strongly with the earlier time point (P = .001) using a level of 10(-4) or higher to define per...Continue Reading

Associated Clinical Trials

References

Jan 9, 2001·Hematology/oncology Clinics of North America·N GökbugetD Messerer
Feb 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Forida Y MortuzaLetizia Foroni
Feb 20, 2004·Proceedings of the National Academy of Sciences of the United States of America·Beate SchwerStewart Shuman
Aug 6, 2004·The New England Journal of Medicine·Amy HollemanWilliam E Evans
Sep 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xavier ThomasDenis Fiere
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott A Armstrong, A Thomas Look
Oct 1, 2005·Blood·Monika BrüggemannUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Jan 13, 2006·The New England Journal of Medicine·Ching-Hon Pui, William E Evans
Feb 9, 2007·Leukemia·V H J van der VeldenUNKNOWN European Study Group on MRD detection in ALL (ESG-MRD-ALL)

❮ Previous
Next ❯

Citations

Oct 1, 2011·Current Treatment Options in Oncology·Rob SellarHillard M Lazarus
Apr 29, 2010·Current Hematologic Malignancy Reports·Theis H TerweyRenate Arnold
Mar 1, 2012·Current Hematologic Malignancy Reports·Dario Campana
Jul 12, 2011·Current Oncology Reports·Joseph M Brandwein
Sep 11, 2010·International Journal of Hematology·Misato KikuchiMasahiro Imamura
Mar 17, 2012·Japanese Journal of Clinical Oncology·Teruhisa AzumaUNKNOWN Japan Clinical Oncology Group-Lymphoma Study Group (JCOG-LSG), Tokyo, Japan
Aug 29, 2009·Current Opinion in Oncology·Ryan J Mattison, Richard A Larson
Jan 12, 2012·Current Opinion in Oncology·Samer K KhaledStephen J Forman
Aug 5, 2009·Current Opinion in Hematology·Hans-Jochem KolbChristoph Schmid
Aug 5, 2009·Current Opinion in Hematology·Tsila Zuckerman, Jacob M Rowe
Mar 23, 2011·Biochemistry. Biokhimii︠a︡·E V Chetverina, A B Chetverin
Dec 17, 2009·Hematology·Anthony H Goldstone, Jacob M Rowe
Jan 18, 2011·Hematology·Dario Campana
Mar 24, 2012·Blood·Nicola GökbugetUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Dec 22, 2012·Blood·Renato Bassan
Apr 4, 2013·Leukemia & Lymphoma·Michael S MathisenElias Jabbour
Aug 23, 2011·Leukemia & Lymphoma·Satoshi Nishiwaki, Koichi Miyamura
Jun 19, 2014·Expert Review of Molecular Diagnostics·Amin Ben LassouedJean Gabert
May 20, 2015·Expert Opinion on Biological Therapy·Britny RogalaMeir Wetzler
May 23, 2015·European Journal of Haematology·Cyril ŠálekUNKNOWN Czech Leukemia Study Group - for Life (CELL)
Apr 14, 2015·Expert Opinion on Biological Therapy·Moreno FestucciaBenedetto Bruno
Jan 21, 2016·The New England Journal of Medicine·Michael J Burke
Dec 30, 2015·Clinical Lymphoma, Myeloma & Leukemia·Luisa GiacconeFilippo Marmont
Dec 4, 2012·Best Practice & Research. Clinical Haematology·Dan Douer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.